IL2 and a synthetic agonist (posphostym) can expand, by one hundred-fold, γδ T-cells which retain an efficient and stable ability to kill plasma cell lines and primary human myeloma cells (12). The gene discussed is IL2; the disease is plasma cell myeloma.